Marine Origin Agents for Therapy of Neglected Diseases

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (31 August 2018) | Viewed by 3124

Special Issue Editor

Special Issue Information

Dear Colleagues,

Neglected Tropical Diseases (NTDs) are a group of 17 chronic and disabling infections affecting more than one billion people worldwide, primarily in extreme poor locations. The neglected designation comes from the reduced financial investment into research and development of new drugs, and because there is lack of public awareness in high-income countries. Because NTDs are linked to poor socioeconomic and hygienic conditions, they could also be termed diseases of neglected populations.

Notwithstanding the recent partial successes in the struggle to eliminate or even eradicate some NTDs, which have been achieved by WHO (World Health Organization) strategies of, for example, disease monitoring, vector control and preventive chemotherapy, the development of new, safe and affordable drugs remains an urgent need. In this context researchers have turned their attention to nature during the last decades, trying to identify compounds that can be used against NTDs. Marine organisms, including plants thriving in marine environments (halophytes) have been increasingly been recognised over the past few decades as a source of unique and novel biologically active natural products. This Special Issue, “Marine Origin Agents for Therapy of Neglected Diseases”, aims to highlight the importance to unlock the potential of marine organisms as sources of novel molecules to control neglected diseases. We welcome submissions from scientists and academics from across the world.

Dr. Luísa Custódio
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • marine natural products
  • marine invertebrates
  • marine microorganisms
  • marine alga
  • halophytes
  • neglected tropical diseases
  • drug discovery

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 1474 KiB  
Article
Potential Utilization of a Polysaccharide from the Marine Algae Gayralia oxysperma, as an Antivenom for Viperidae Snakebites
Mar. Drugs 2018, 16(11), 412; https://doi.org/10.3390/md16110412 - 27 Oct 2018
Cited by 5 | Viewed by 2800
Abstract
Worldwide, snakebites have serious implications for human health. The administration of antivenom is the official treatment used to reverse the toxic activities of envenomation. However, this therapy is not efficient to treat the local effects, leading to the amputation or deformity of affected [...] Read more.
Worldwide, snakebites have serious implications for human health. The administration of antivenom is the official treatment used to reverse the toxic activities of envenomation. However, this therapy is not efficient to treat the local effects, leading to the amputation or deformity of affected limbs. As such, alternative treatments are needed. Here, we analyze the ability of a polysaccharide from the green marine alga Gayralia oxysperma (Go3) to inhibit the effects of venom from Bothrops jararaca and Lachesis muta. B. jararaca or L. muta venoms were incubated together with sulfated heterorhamnans from Go3, and the in vitro (coagulation, proteolytic, and hemolytic) and in vivo (hemorrhagic, myotoxic, edematogenic, and lethal) activities of venoms were assessed. Additionally, Go3 was injected before and after the injection of venoms, and the toxic activities were further tested. When incubated with the venoms, Go3 inhibited all activities, though results varied with different potencies. Moreover, Go3 neutralized hemorrhagic, myotoxic, and edematogenic activities when injected before or after injection with B. jararaca and L. muta venom. Go3 also blocked the coagulation of plasma in mice caused by the venoms in an ex vivo test. Therefore, Go3 has the potential to be used as antivenom for B. jararaca and L. muta bites, notably exhibiting higher efficacy on L. muta venom. Full article
(This article belongs to the Special Issue Marine Origin Agents for Therapy of Neglected Diseases)
Show Figures

Figure 1

Back to TopTop